| Cell Therapeutics, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110196123 | PROCESS FOR THE PREPARATION OF POLY-alpha-GLUTAMIC ACID AND DERIVATIVES THEREOF - The invention relates to an improved process for the preparation of poly-α-glutamic acids which comprises the polymerization of tertiary γ-esters of α-glutamic acid N-carboxy anhydride with appropriate solvents and initiators, followed by acid hydrolysis of the resulting poly-α-glutamic acid-γ-ester. The process is particularly advantageous in that it allows one to carefully control the molecular weight of the resulting poly-α-glutamic acid. The invention also relates to poly-α-glutamic acids capped at the amino terminus with carboxylic acids or amino acids and to a process for the preparation thereof. | 08-11-2011 |
| 20100189726 | LPAAT-BETA INHIBITORS AND USES THEREOF - The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity. | 07-29-2010 |
| 20100151582 | METHOD FOR DETERMINING THE AMOUNT OF CONJUGATED TAXANE IN POLYGLUT ACID-TAXANE CONJUGATES - The invention relates to a method for determining the amount of conjugated taxane, in particular paclitaxel, in a PGA-taxane conjugate said method comprising: a) reacting the PGA-taxane conjugate with a compound formula (I): R | 06-17-2010 |
| 20090298762 | CONJUGATES OF BIOLOGICALLY ACTIVE PROTEINS HAVING A MODIFIED IN VIVO HALF-LIFE - Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide. | 12-03-2009 |
| 20090130229 | Antitumor uses of compound - The use of an arylidene 2-indolinone derivative for treating tumors involving Met, PDGF-R, FGF-RI, FGF-R3 or Kit tyrosine kinases, or a Ret oncoprotein which includes a MEN2-associated mutation is disclosed. | 05-21-2009 |
| 20090099183 | PYRIMIDINES AND USES THEREOF - The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor-cells. | 04-16-2009 |
| 20080261980 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents - The invention relates to the use of compounds of general formula (I), in which R | 10-23-2008 |
| 20080255099 | Use of Diketodithiopiperazine Antibiotics for the Preparation of Antiangiogenic Pharmaceutical Compositions - The invention relates to the use of diketodithiopiperazine antibiotics, in particular chaetocin and gliotoxin, for the preparation of pharmaceutical compositions for antitumor therapy. | 10-16-2008 |
